Neurocrine Biosciences
NBIX
NBIX
133 hedge funds and large institutions have $1.68B invested in Neurocrine Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
67% less call options, than puts
Call options by funds: $17.4M | Put options by funds: $52.4M
Holders
133
Holding in Top 10
2
Calls
$17.4M
Puts
$52.4M
Top Buyers
| 1 | +$19.7M | |
| 2 | +$19.7M | |
| 3 | +$16.8M | |
| 4 |
VAM
Visium Asset Management
New York
|
+$15.1M |
| 5 |
CCI
Columbus Circle Investors
|
+$12.1M |
Top Sellers
| 1 | -$734M | |
| 2 | -$22.3M | |
| 3 | -$18.2M | |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.5M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.29M |